Lurasidone is a novel atypical
antipsychotic with high affinity for
dopamine D2,
serotonin 5-HT7 and 5-HT2A receptors. We previously reported that
lurasidone and the selective
5-HT7 receptor antagonist,
SB-656104-A improved learning and
memory deficits induced by
MK-801, an
N-methyl-d-aspartate (
NMDA) receptor antagonist, in the rat passive avoidance test. In this study, we first examined the role of the
5-HT7 receptor antagonistic activity of
lurasidone in its pro-cognitive effect to ameliorate MK-801-induced deficits in the rat passive avoidance test. The
5-HT7 receptor agonist, AS19, (2S)-(+)-5-(1,3,5-trimethylpyrazol-4-yl)-2-(dimethylamino)
tetralin, (3 mg/kg, s.c.) completely blocked the attenuating effects of
lurasidone (3 mg/kg, p.o.), highlighting the importance of
5-HT7 receptor antagonism in the pro-cognitive effect of
lurasidone. AS19 (3 mg/kg, s.c.) also blocked the ameliorating effect of
SB-656104-A (10 mg/kg, i.p.) in the same experimental paradigm. To further extend our observation, we next tested whether
5-HT7 receptor antagonism still led to the amelioration of MK-801-induced deficits when combined with D2 and
5-HT2A receptor antagonists, and found that
SB-656104-A (10 mg/kg, i.p.) significantly ameliorated MK-801-induced deficits even in the presence of the D2 receptor antagonist
raclopride (0.1 mg/kg, s.c.) and
5-HT2A receptor antagonist
ketanserin (1 mg/kg, s.c.). Taken together, these results suggest that the
5-HT7 receptor antagonistic activity of
lurasidone plays an important role in its effectiveness against MK-801-induced deficits, and may contribute to its pharmacological actions in patients with
schizophrenia.